Rockwell Medical Technologies, Inc. Receives Nasdaq Notification of Continued Nasdaq Listing

Business Wire, July 12, 2001

Business Editors

WIXOM, Mich.--(BUSINESS WIRE)--July 12, 2001

Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has been notified by Nasdaq that the Company has demonstrated compliance with Nasdaq's listing requirements and that the Company's common stock will continue to be listed on the Nasdaq SmallCap Market(TM).

The Company had previously been notified by Nasdaq that its common stock could be de-listed from Nasdaq because the Company had failed to maintain a closing bid price of at least $1.00 per share. As this issue has been resolved satisfactorily, the matter is now closed.

Robert L. Chioini, Chairman, CEO and President of Rockwell Medical Technologies, Inc., stated, "We are very pleased that the Company received this communication. It further demonstrates the forward progress of the Company."

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte(TM) Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Visit Rockwell's website at www.rockwellmed.com for more information.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.